Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
VO

NASDAQ · VOR

Vor Biopharma Inc.

Healthcare · Biotechnology

$19.68

Down-$1.23 (-5.88%)

Updated Nov 1, 2026, 5:01 PM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
83.27M
P/E ratio
-0.03
Dividend yield
0.00%
52-week range
$6.50 – $26.00
Volume
759.6K
Avg. volume
1.34M

Price performance · VOR

VOR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

VOR closed at $19.68 after 20 trading sessions, up 5.92% for the selected period.

Last close
$19.68
Period change
+5.92%
Period low
$18.03
Period high
$20.91
Daily close
View OHLC price history
VOR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$19.98$20.47$19.3701$19.68759.6K
Oct 29, 2026$20.80$21.74$20.66$20.91968.25K
Oct 28, 2026$19.50$20.81$19.275$20.651.01M
Oct 27, 2026$18.36$19.56$18.0154$19.54770.83K
Oct 26, 2026$18.33$18.44$17.70$18.33470.34K
Oct 23, 2026$18.67$18.81$17.95$18.26720.97K
Oct 22, 2026$18.87$19.44$18.65$18.94723.52K
Oct 21, 2026$19.18$19.79$18.791$18.94817.61K
Oct 20, 2026$18.06$19.55$18.00$19.03796K
Oct 19, 2026$18.37$18.72$17.73$18.04724.82K
Oct 16, 2026$19.45$19.45$17.9998$18.03735.16K
Oct 15, 2026$18.85$20.25$18.78$19.34696.79K
Oct 14, 2026$18.79$19.74$18.55$18.75927.18K
Oct 13, 2026$19.50$19.95$18.975$19.06949.44K
Oct 12, 2026$19.79$20.52$19.55$19.80867.44K
Oct 9, 2026$18.99$20.27$18.85$19.901.1M
Oct 8, 2026$18.64$19.88$18.08$19.131.41M
Oct 7, 2026$18.09$18.895$17.86$18.78563.09K
Oct 6, 2026$18.85$18.87$17.97$18.31472.84K
Oct 5, 2026$18.63$19.18$18.07$18.58648.6K

Latest VOR news

The latest Smart Investors Daily articles mentioning VOR.

Stock researchCompany · Overview

VOR research

Overview

Company profile and research snapshot.

Company profile

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$58.00
Implied upside
—
Analysts
—
VOR recent ratings
DateFirmRatingTarget
Oct 21, 2026William BlairOutperform—
Aug 12, 2026WedbushNeutral—
May 18, 2026HC Wainwright & Co.Buy—
May 14, 2026WedbushNeutral—
Apr 15, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p<0.001) 89% and 81% reductions in risk of confirmed ≥30% and ≥40% eGFR declines, respectively Proteinuria reductions sustained through 104 weeks following transition to every-other-week dosing; favorable safety profile BOSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today

Yahoo · Oct 8, 2026

Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus

Vor Biopharma (VOR) drew fresh attention after releasing a post hoc analysis of its Phase 3 gMG trial for telitacicept, highlighting response depth, durability over 48 weeks, and a consistent safety profile. The telitacicept update landed after a choppy stretch for Vor Biopharma, with the latest 1-day share price return of 2.57% only partly offsetting a 30-day share price decline of 25.03%. The year-to-date share price return of 61.34% contrasts with a 1-year total shareholder return that is...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By